CXCL10 Overview
Molecule Name
C-X-C motif chemokine ligand 10
Synonyms
C-X-C motif chemokine 10,10 kDa interferon gamma-induced protein,Gamma-IP10,IP-10,Small-inducible cytokine B10,CXCL10(1-73),CXCL10,INP10, SCYB10
Drug Development Progress
Drugs in Clinical Trials2
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Protein 10 From Interferon (Gamma)-Induced Cell Line，CXCL10，INP10，SCYB10，C-X-C motif chemokine 10，10 kDa interferon gamma-induced protein，IP-10，C-X-C Motif Chemokine Ligand 10，Small Inducible Cytokine Subfamily B (Cys-X-Cys)， Member 10，Chemokine (C-X-C Motif) Ligand 10，Small-Inducible Cytokine B10，Chemokine CXCL10，Interferon-Inducible Cytokine IP-10，Gamma IP10，Gamma-IP10，GIP-10，IFI10，Crg-2，Mob-1，C7
Background
C-X-C Motif Chemokine Ligand 10 (CXCL10) is a pro-inflammatory chemokine secreted by a wide spectrum of cells. It is involved in multiple mechanisms and reported to have pleiotropic effects, including immune cell migration and attraction to inflammation sites, angiogenesis, and cancer cell growth. CXCL10 is produced by pancreatic islet cells upon inflammatory stress and is specifically recognized by C-X-C Motif Chemokine Receptor 3 (CXCR3) which is expressed by activated T-lymphocytes and other immune cells.
CXCL10 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| JT-02 (JYANT Technologies) | JT-02 | Phase 2 Clinical | Jyant Technologies | Inflammatory Bowel Diseases | Details |
| NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd | Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Squamous Cell Carcinoma of Head and Neck | Details |